Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
Hemorrhagic cystitis is a major complication of high-dose cyclophosphamide therapy used in preparation for allogeneic or autologous bone marrow transplantation. Although previous reports had suggested that the sulfhydryl-containing compound mesna might be superior to forced diuresis in preventing hemorrhagic cystitis, there were concerns about the effect of mesna on engraftment in these studies. To address these concerns, 100 patients were randomized to receive mesna or forced saline diuresis while undergoing bone marrow transplant conditioning with regimens that included high-dose cyclophosphamide. To try to minimize the likelihood of graft rejection, patients who were being transplanted with cyclophosphamide as a sole agent were excluded from the study. After randomization and administration of therapy, patients were monitored by microscopic and dip-stick urinalyses; they were also followed for effects of therapy on engraftment. The incidence of consistent or severe hematuria was 33% in the mesna arm and 20% in the hyperhydration arm (P = .31). Severe bleeding occurred in 12.5% of mesna patients and 7.5% of hyperhydration patients (P = .71). No unexpected toxicities were encountered, and engraftment times did not differ. Based on this randomized trial of 100 patients, we conclude that mesna and hyperhydration are equally effective in preventing cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation patients.
Shepherd
J D
JD
Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver, Canada.
Pringle
L E
LE
Barnett
M J
MJ
Klingemann
H G
HG
Reece
D E
DE
Phillips
G L
GL
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D005260:Female; D005440:Fluid Therapy; D006470:Hemorrhage / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D008297:Male; D015080:Mesna / Q000627:therapeutic use*; D008875:Middle Aged
D003520:Cyclophosphamide; D015080:Mesna